Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)

Biocomposites to showcase innovations in infection management at EBJIS 2024

Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products

Biocomposites to distribute its NanoBone® product range in the UK

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.

Biocomposites expands its international presence by opening new sales and distribution office in Italy

Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2

Biocomposites exceeds revenue expectations and takes a big step forward in its research and development

STIMULAN® now available in South Africa

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK

Biocomposites announces new territories approved to promote STIMULAN­® as an antibiotic carrier in bone and soft tissue

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Biocomposites appoints two new Directors to strengthen its team for its next phase of growth

Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform

Biocomposites adds proprietary NanoBone® technology to its portfolio through the acquisition of Artoss GmbH

A year of record sales and company growth

Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

Biocomposites to present latest STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Biocomposites appoints Group Chief Financial Officer and New UK General Manager

Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade

Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

A year of international growth and product advancement

Biocomposites signs distribution agreement with NuVasive Specialized Orthopedics to supply STIMULAN® in Germany

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Biocomposites to present data on STIMULAN® and genex® at American Academy of Orthopaedic Surgeons Annual Meeting

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Biocomposites announces new approval for STIMULAN® to treat bacterial infection

Biocomposites Launches Biocomposites Companion

Biocomposites appoints Davina Lawrence as National Sales Director

Transformational year for Biocomposites

Biocomposites signs new exclusive distributor in Australia

Biocomposites announces STIMULAN® products added to NHS Supply Chain

Biocomposites announces new CE Mark for STIMULAN®

Biocomposites Appoints President, Biocomposites Inc.

Biocomposites Status on Novel Coronavirus (COVID-19)

Biocomposites announces U.S. launch of new STIMULAN® Rapid Cure 3cc product